CompletedPhase 2NCT00003615
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Timothy M. Kuzel, MDRobert H. Lurie Cancer Center
- Intervention
- denileukin diftitox(biological)
- Enrollment
- 77 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 1999
Study locations (10)
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
- Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States
- Hunterdon Regional Cancer Center, Flemington, New Jersey, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Morristown Memorial Hospital, Morristown, New Jersey, United States
- Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
- Overlook Hospital, Summit, New Jersey, United States
- CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003615 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn